Medivir's CEO to BioStock: "Fostrox is unique in its kind"

Medivir's phase I study, which established clinical proof-of-concept for fostrox as monotherapy in patients with liver cancer, has been published in the Journal of Hepatocellular Carcinoma. The study shows that fostrox is safe and well-tolerated with preliminary anti-tumour activity, confirming that the drug specifically targets cancer cells in the liver while sparing healthy cells. BioStock reached out to CEO Jens Lindberg for a comment.

Read the article at biostock.se:

https://www.biostock.se/en/2024/10/medivirs-ceo-fostrox-is-unique-in-its-kind/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/